bluebird bio Revenue and Competitors
Estimated Revenue & Valuation
- bluebird bio's estimated annual revenue is currently $53.6M per year.
- bluebird bio received $632.5M in venture funding in July 2018.
- bluebird bio's estimated revenue per employee is $97,901
- bluebird bio's total funding is $484M.
- bluebird bio's current valuation is $612M. (January 2022)
- bluebird bio has 548 Employees.
- bluebird bio grew their employee count by -22% last year.
bluebird bio Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is bluebird bio?
We are leading the gene therapy revolution. Our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing - providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. We have a lot of energy, and it's not just the abundance of coffee that keeps us going. Find out what sparks our excitement and inspires us every day.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
bluebird bio News
Bluebird bio's beta thalassemia gene therapy treatment Zynteglo might have some grounds to support an anticipated high price point,...
Investment climate for publicly-traded biotech stocks poor; Despite recent layoffs, Bluebird Bio's cash position is weak; Bluebird Bio's revenue...
The multiple R&D, regulatory and commercialization setbacks have hit home for bluebird bio. Hoping to keep the business afloat, the gene therapy specialist...
bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process. Proceeds from the financing will support ongoing R ...
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies CAMBRIDGE, Mass. - (BUSINESS WIRE) - June 7, 2021- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Ph ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
bluebird bio Funding
|2011-04-21||$30.0M||Undisclosed||ARCH Venture Partners, Third Rock Ventures||Article|
|2012-07-26||$60.0M||D||Deerfield Partners, RA Capital||Article|
|2013-06-03||$60.0M||D||Deerfield Partners, RA Capital||Article|
|2015-06-25||$575.0M||BofA Merrill Lynch||Article|
|2016-12-08||$200.0M||Undisclosed||Goldman, Sachs & Co||Article|
|2017-06-28||$350.0M||Undisclosed||Goldman Sachs & Co. LLC||Article|